Suchergebnisse - "Baynes, Kevin"

PubPharm (24)

1

Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19

enthalten in: Diabetes care | 2022

von Khunti, K. | Ruan, Y. | Davies, J. | +112

CommentIn: Diabetes Care. 2022 Dec 1;45(12):2806-2807. - PMID 36455120

2

An update to collaborating for improving diabetes care in Ealing, London : investment, integration and innovation, years 2011–2020

enthalten in: Practical Diabetes | 2022

von Chandok, R. | Baynes, K. | Birnbaum, M.

3

Collaborating for improving diabetes care in Ealing, London : a time for cautious optimism, years 2011 to 2018

enthalten in: Practical Diabetes | 2019

von Chandok, R. | Baynes, K. | Willis, T. | +2

4

Systemic effects of periodontitis treatment in patients with type 2 diabetes : a 12 month, single-centre, investigator-masked, randomised trial

enthalten in: The lancet. Diabetes & endocrinology | 2018

von D'Aiuto, F. | Gkranias, N. | Bhowruth, D. | +33

CommentIn: Lancet Diabetes Endocrinol. 2018 Dec;6(12):917-919. - PMID 30472991

5

Weekend specialist intensity and admission mortality in acute hospital trusts in England : a cross-sectional study

enthalten in: Lancet (London, England) | 2016

von Aldridge, C. | Bion, J. | Boyal, A. | +115

CommentIn: Lancet. 2016 Jul 9;388(10040):108-11. - PMID 27178478

6

Renal tubular acidosis type 4 in pregnancy

enthalten in: BMJ case reports | 2016

von Jakes, A. | Baynes, K. | Nelson-Piercy, C.

7

Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose

enthalten in: The Journal of clinical endocrinology and metabolism | 2014

von Tan, T. | Salem, V. | Troke, R. | +10

8

Combination of Peptide YY3–36 with GLP-17–36 amide Causes an Increase in First-Phase Insulin Secretion after IV Glucose

enthalten in: The journal of clinical endocrinology & metabolism | 2014

von Tan, T. | Salem, V. | Troke, R. | +10

9

Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia

enthalten in: Diabetes | 2013

von Tan, T. | Field, B. | McCullough, K. | +11

10

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

enthalten in: Diabetes | 2013

von Tan, T. | Field, B. | McCullough, K. | +11